On May 15, 2023 Immedica’s partner Actinium Pharmaceuticals, Inc. reported that an abstract on the Iomab-B SIERRA trial results has been accepted for an oral presentation at the upcoming European Hematology Association (EHA) (Free EHA Whitepaper) 2023 Congress (EHA) (Free EHA Whitepaper) which will be held in Frankfurt, Germany, June 8-11, 2023 (Press release, Immedica Pharma, MAY 15, 2023, View Source [SID1234631723]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract includes data from Actinium’s controlled phase 3 study, SIERRA , comparing the efficacy of Iomab-B based conditioning, a first-in-class targeted radiotherapy, versus physician’s choice of conventional care in patients ≥55 years of age with relapsed/refractory acute myeloid leukemia (AML). This latest acceptance of the SIERRA trial results at EHA (Free EHA Whitepaper), a major medical conference, is helping spread awareness about the potential of Iomab-B in facilitating allogeneic hematopoietic stem cell transplantations (HSCT) for patients with relapsed/refractory AML.
In April 2022 Immedica entered into a license and supply agreement with Actinium Pharmaceuticals, Inc. for Iomab-B in Europe, the Middle East and North Africa.
Details of the EHA (Free EHA Whitepaper) presentation are as follows:
Presentation Title: SIERRA trial results with a targeted radiotherapy, Iomab-B, a myeloablative conditioning with reduced intensity tolerability yields high CR, long term survival in HSCT ineligible active r/r AML
Session Type/Title: Oral / SCT Clinical
Date and Time: June 10, 11:30am – 12:45pm CEST